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Background: Satisfactory sample preparation for mass spectrometry-based analysis is a critical step in the
proteomics workflow. The quality and reproducibility of sample preparation can determine the coverage and
confidence of proteomics results. Up to date, several methodologies have been described to produce suitable
peptides for mass spectrometry analysis, followed by strategies for enrichment of post-translational modified
peptides, if desired. Among them, the filter-aided sample preparation (FASP) has been introduced as a method to
allow for removal of denaturants, reductants, alkylators, lipids and nucleic acids prior to trypsin digestion. Despite
the high proteolytic digestion and contaminant removal efficiency described for this method, filter failure and
consequently complete sample loss can discourage the use of this approach by the proteomic community.
Results: As judged by our quality controls, we were able to perform reliable and reproducible FASP for mass
spectrometry analysis that allowed the quantification of 2141 proteins and 3694 phosphopeptides from as little as
20 and 320 μg of protein lysate from acute myeloid leukemia (AML) patients, respectively. Using the immobilized
metal ion affinity chromatography (IMAC) method resulted in samples specifically enriched in phosphopeptides and
allowed the quantification of a high number of both di- and multi-phosphopeptides in addition to the abundant
mono-phosphopeptides. The workflows’ high reproducibility from three biological replicates was demonstrated by
the similar number of quantified proteins and localized phosphosites, and confirmed by the similar distributions of
their molecular functions. We found that the combination of the FASP procedure with StageTip mixed-mode
fractionation and IMAC are excellent workflows for the reproducible and deep study of AML proteomes and
phosphoproteomes, respectively.
Conclusions: The FASP procedure can be carried out without the risk of filter failure by performing a simple test of
the filter quality before adding the protein sample. Herein, we demonstrate an efficient and reproducible
FASP-based pipeline for the proteomic and phosphoproteomic analysis of AML patient samples which also can be
used for the analysis of any other protein samples.
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AML is an aggressive hematopoietic malignancy character-
ized by a rapid growth of immature white blood cells that
accumulate in the bone marrow hampering the production
of normal blood cells [1]. AML has several subtypes that
are classified according to cellular morphology,
hematopoietic lineage and gene translocations and muta-
tions [2]. Even though the genotypic classification and
cytogenetic analyses (e.g. PML-RARA fusion protein) are
important for prognostication and identification of possible
therapeutic targets, more recent studies have suggested
that analysis of cancer phenotypes could contribute with
information on both prognosis and new therapies in hu-
man malignancies [3, 4], including AML [5]. Proteomic
profiling from liquid chromatography-mass spectrometry
(LC-MS)-based analyses will then be important for our un-
derstanding of the molecular mechanisms leading from
genetic abnormalities to leukemic transformation, for the
identification of new prognostic biomarkers and thera-
peutic targets that could improve the efficacy of antileuke-
mic treatments in a near future. However, the variable
number of blast cells in AML patient samples and the sen-
sitivity of current MS equipment available for proteomic
and phosphoproteomic studies are limiting factors in the
discovery of new AML biomarkers. Moreover, AML cells
express large amount of proteases [6, 7] which immediately
will catalyse proteolytic degradation at the time of cell lysis.
Therefore it is crucial to prepare AML samples for MS
analysis according to proteomic and phosphoproteomic
methodologies that minimizes proteolytic degradation and
allow high protein and phosphorylation coverage.
Classical methods to produce peptides are one dimen-
sional polyacrylamide gel electrophoresis (1D-PAGE) [8] or
2D-PAGE [9] followed by in-gel trypsin digestion and in-
solution trypsin digestion with urea, sodium deoxycholate
or RapiGest to solubilize proteins [10]. A novel approach
to digest proteins in spin filters using sodium dodecyl sul-
fate (SDS) as denaturant and as an efficient inactivator of
proteases was first described by Manza et al. [11] but the
method did not become popular before being presented as
FASP, which incorporated urea to successfully remove SDS,
by Wisniewski et al. [12]. Recently, optimized protocols
of in-solution digestion using trifluoroethanol [13] or
guanidinium hydrochloride containing tris(2-carbox-
yethyl)phosphine and chloroacetamide that allow sim-
ultaneous reduction and alkylation [14] along with new
in-StageTip [15] and gel-aided sample preparation (GASP)
[16] methods have been reported to achieve high number
of protein identifications quantified accurately using last
generation of benchtop quadrupole ultra-high-field Orbi-
trap MS.
In the FASP method, SDS-solubilized proteins are di-
luted with 8 M urea to reduce the concentration of SDS
compatible with the use of the spin filter. Proteins in thefilter unit are alkylated in the urea buffer and are then
exchanged into ammonium bicarbonate (Ambic) buffer
for enzymatic digestion. The eluting peptides can then
be analysed by MS with no further processing than
desalting, or can be fractionated with small scale chro-
matography in StageTips using strong anion exchange
disks to increase proteomic coverage [17, 18]. Alterna-
tively, the use of two consecutive enzymes such as Lys-C
and trypsin in the spin filter and the following analysis
of the two peptide populations separately have the po-
tential to increase the identification of proteins and
phosphorylation sites by 40 % [19, 20].
Since the introduction of the FASP procedure, more and
more proteomic workflows have included this filter-based
method because of its efficient proteolysis and increased
sensitivity when compared to in solution-digestion ap-
proaches. However, it is well known that typically 40–60 %
of the sample can not be recovered in the filtrate because
of filter clogging probably produced from poorly digested
proteins, large peptides, nucleic acids and lipids. Moreover,
the sample of interest can be lost in case of occasional fil-
ter failure. A recent re-evaluation of the FASP protocols
by Wisniewski has identified several experimental condi-
tions that allow efficient protein processing, such as the
amount of sample and composition of the digestion buffer,
and circumvent the damage of the ultrafiltration mem-
brane during centrifugation [21].
Here, we describe the application of classical FASP for
the preparation of AML patient samples for proteomic
and phosphoproteomic analysis. In our step-wise protocol,
we have included an initial key test of the spin filters that
detects faulty filters and prevent a complete sample loss.
Our tips will also help to recover a sample in case of filter
failure during the FASP procedure. In a recent study [22]
we have shown that while the FASP method, without frac-
tionation of the sample before LC-MS analysis, could
quantify 1480 proteins, the FASP method followed by a
small scale fractionation in StageTip using SDB-RPS (styr-
enedivinylbenzene reverse-phase sulfonate; also known as
mixed mode chromatography) disks [15] was able to
quantify 2141 proteins. The SDB-RPS fractionation out-
performed other fractionating chromatography strategies
such as strong cation exchange in our workflow tests [22].
These comparisons were performed in stable isotope
labelling by amino acids in cell culture (SILAC)-la-
belled experiments to test different methods of sam-
ple preparation.
Therefore, we have coupled the FASP method with the
mixed mode StageTip fractionation to increase the prote-
ome coverage and with the IMAC approach for enrich-
ment of AML phosphopeptides (Fig. 1). As we will
demonstrate, our presented FASP-based pipeline results in
a safe procedure for a deep and reproducible analysis of
the proteome and phosphoproteome from patient samples.
AML patient sample
Proteomics-FASP
20 µg sample + 
10 µg super-SILAC mix 
Phosphoproteomics-FASP
320 µg sample + 













Fig. 1 Proteomic and phosphoproteomic workflows. Production of peptides with the FASP method is followed by StageTip fractionation and
IMAC-phosphoenrichment to prepare samples for the proteome and phosphoproteome data sets, respectively. Red circles illustrate the phospho
group of phosphopeptides
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The results from the use of the FASP method to quantify
the proteome and phosphoproteome of AML samples
were obtained after the initial filter performance test as
describe below to detect filter failure. Typically, 16–
22 μg and 210–258 μg of peptides were recovered after
digestion of proteomic and phosphoproteomic samples,
respectively. We found that the filter performance test
was a crucial step in our FASP workflow as faulty filters
only recovered 0–1 μg of peptides according to absorb-
ance measurements at 280 nm.
Proteome of AML patient samples
The analysis of three AML patient samples processed
with the FASP procedure and SDB-RPS fractionation
resulted in 2299, 2191 and 1933 SILAC-quantified
protein groups of which more than 94 % were quanti-
fied with more than one peptide in all three samples
(Fig. 2a). The quantified peptide numbers were 17288,
16740 and 14415 in the samples, respectively. The
number of quantified proteins and peptides with theFASP method coupled to a mixed mode fractionation
here in this study was similarly observed in our previ-
ous testing study of several methods of sample prep-
aration [22].
Analysis of the individual fractions (fraction x1, x2 and
bufX) shows that different peptides are eluted into the
different fractions, although there is an overlap between
adjacent fractions (Fig. 2b), as one would expect. Less
than 10 % of the peptides were quantified in all three
fractions. The last fraction (bufX) always contained less
peptides compared to the other fractions. The proteins
identified in the three AML patient samples had similar
molecular functions (Fig. 2c), and were mostly enriched
with proteins involved in RNA binding (6.8, 6.9 and
6.8 % of the mapped proteins), transporter activity (6.1,
6.0 and 5.8 % of the mapped proteins) and catalytic ac-
tivity (6.0, 5.9 and 6.6 % of the mapped proteins). For
sample B a larger percentage of the proteins were in-
volved in hydrolase activity (2.3 %), while sample A and
C contained more proteins involved in oxidoreductase
activity (2.1 and 2.5 %, respectively).
A B
C
Sample A Sample B Sample C
MF % proteins MF % proteins MF % proteins
RNA binding 6.8 RNA binding 6.9 RNA binding 6.8
Transporter activity 6.1 Transporter activity 6.0 Catalytic activity 6.6
Catalytic activity 6.0 Catalytic activity 5.9 Transporter activity 5.8
Structural constituents 
of ribosome
3.7 Structural constituents 
of ribosome
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Fig. 2 Proteome analysis of three AML patient samples. a Number of quantified protein groups and protein groups quantified with more than
one peptide in sample A, B and C are shown at the y-axis to the left; and the number of quantified peptides is shown at the y-axis to the right.
b Venn diagrams displaying the quantified peptides in the different SDB-RPS fractions (x1, x2 and bufX) of sample A, B and C. c The nine highest
enriched molecular functions (MF) annotated by Funrich in the three samples were compared
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Analysis of three IMAC-phosphoenriched AML samples
produced directly after the FASP procedure described
here found 3666, 3850 and 3567 unique SILAC-quantified
phosphopeptides and 3013, 3158 and 2938 class I-
localized (probability >0.75) phosphosites in the three dif-
ferent AML samples, respectively (Fig. 3a). The number of
quantified phosphosites with the FASP method coupled to
IMAC enrichment here in this study was similarly ob-
served in our previous testing study of several methods of
phosphopeptide enrichment [22].As expected, most of the phosphosites showed phosphor-
ylation at serine and threonine residues as only 20, 26 and
18 phosphotyrosine sites were found in the three different
samples. Besides mono-phosphopeptides, the IMAC meth-
odology enriched di- and multi (more than 2)-phosphopep-
tides: 687, 783 and 675 quantified di-phosphopeptides
and 99, 125 and 89 quantified multi-phosphopeptides
were observed in the three different AML samples,
respectively (Fig. 3b). The specificity of the IMAC en-
richment was between 95 % and 98 % among the
three samples.
CA B
Sample A Sample B Sample C
MF % proteins MF % proteins MF % proteins
Transcription regulatory 
activity
9.9 Transcription regulatory 
activity
9.7 Transcription regulatory 
activity
8.9
Transcription factor activity 7.4 Transcription factor activity 7.1 RNA binding 7.1
RNA binding 7.2 RNA binding 6.8 Transcription factor activity 6.9
DNA binding 5.7 DNA binding 6.2 DNA binding 5.8
Protein serine/threonine 
kinase activity
4.7 Protein serine/threonine 
kinase activity





2.9 Transporter activity 3.1 Receptor signalling complex 
scaffold activity
3.1
Transporter activity 2.6 Receptor signalling complex 
scaffold activity
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Fig. 3 Phosphoproteome analysis of three AML patient samples. a Number of quantified phosphopeptides with normalized SILAC ratios by MaxQuant
and class I-localized phosphosites. b Distribution of serine-, threonine- and tyrosine-phosphosites; and mono-, di- and multi-phosphopeptides in the
quantified phosphoproteome. c Molecular function enrichment analysis using the FunRich database
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three AML samples was also observed after functional
enrichment analysis. The three AML samples showed
very similar percentages of phosphoproteins in the most
represented categories of molecular function, including
the category of the protein serine/threonine kinase activ-
ity with 4.4–4.7 % of the mapped proteins (Fig. 3c).
Discussion
The discovery of disease biomarkers by MS-based prote-
omic strategies is of current increasing interest due to
the availability of fast and sensitive mass spectrometers
in addition to cohorts of high number of patient sam-
ples. There are several methods to prepare samples forMS-based analysis of whole or partial proteomes and
post translationally modified proteomes. A recent review
by Feist and Hummon have highlighted the advantages
and drawbacks of most of them [23]. However, the choice
of proteomic workflows is not arbitrary and it depends on
the nature and amount of the protein sample, the experi-
ence of the researcher and the resources and equipment
of the lab. Filter-based sample preparations were intro-
duced a decade ago. Up to date, only nearly 65 published
works have used this approach for MS-based proteomic
studies (PubMed, FASP and proteomics used as search
words). Despite the high efficiency proven in those stud-
ies, its multi-step protocol can be found discouraging, es-
pecially when it is accompanied by a filter failure that
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measuring the peptide concentration in the filtered solu-
tions by absorbance reading at 280 nm, for example (see
Results section).
In the FASP-based workflow described here, we intro-
duced an initial test for the optimal performance of the
spin filters that greatly decreases the chance of losing
important samples. Even so and rarely after the initial
quality screening, the filters might fail at later steps of
the protocol. Therefore FASP users should always notice
when the protein samples have been fully filtered as in-
dicated by the lack of the minimal concentrated volume
on top of the filter membrane. Following these indications,
we have shown that our FASP workflow result on the
quantitation of 2141 ± 188 (average ± standard deviation
of the three biological replicates) proteins from 20 μg of
protein lysate from AML patient samples. By adding a
simple IMAC phosphoenrichment workflow without add-
itional sample fractionation, we could quantify 3694 ± 144
phosphopeptides from 320 μg of lysed sample.
The reliability and reproducibility of our FASP-based
protocols for AML patient samples in addition to the
small amounts of protein required for proteome and
phosphoproteome analysis encourages the FASP approach
as an alternative to in-solution and in-gel digestion proce-
dures. Moreover, the use of SDS in the lysis buffer assures
the inactivation of proteases in samples, as the myeloid
blasts in AML, that contain large numbers of diverse hy-
drolases in lytic vacuoles [24].
Our detailed protocols are especially suitable for first-
time FASP users and unexperienced researchers in prote-
ome fractionation and phosphopeptide enrichment.
Conclusions
We here demonstrate a highly reproducible FASP-based
pipeline which advantageously can be used in studies of
proteome and phosphoproteome from AML patients, as
well as in the analysis of any other protein samples. The
methods are simple and produce reasonably depth in the
proteome coverage that might lead to the discovery of
important biosignatures of disease.
Methods
Descriptions of methods are provided followed by de-
tailed step-wise protocols for the proteome and phos-
phoproteome preparations.
AML patients and preparation of primary AML cells
Patients were diagnosed and classified according to the
criteria given in the World Health Organization (WHO)
classification [2]. Unselected patients with high periph-
eral blood blast counts (>10x109/L) and at least 95 % of
circulating mononuclear cells being leukemic blasts after
isolation by density gradient separation (Lymphoprep,Axis-Shield) [25–27] were included in this study. The
cells were stored in liquid nitrogen until used in the
experiments.
Preparation of AML samples for the FASP procedure
Three AML patient samples, named here as sample A,
sample B and sample C, were thawed on ice. The cells
were pelleted by gentle spinning at 170 xg at 4 °C during
5 min. The supernatant was carefully removed and the
cells were resuspended in a buffer containing 4 % SDS and
0.1 M Tris–HCl pH 7.6. Samples were heated at 95 °C for
7 min under mild shaking and sonicated (3 cycles at 30 %
of amplitude for 30 seconds with 1 min rest between cy-
cles) to shear nucleic acids. Cell debris was removed by
centrifugation at 16000 xg for 10 min and the protein con-
centration was determined with the Pierce BCA Protein
Assay kit (Thermo Fisher Scientific) from three independ-
ent readings. Samples were kept at −80 °C.
FASP of AML patient samples
For proteomic labelled studies, 20 μg of each of the three
samples were mixed with 10 μg of a super-SILAC mix
composed of five AML cell lines labelled with isotopes
Arg6 and Lys8 [28]. The mixture was reduced by adding
dithiothreitol (DTT) to 0.1 M and heated at 95 °C for
5 min under mild shaking. SDS in the samples was re-
duced to 0.5 % with the FASP-urea buffer (8 M urea in
0.1 M Tris–HCl pH 8.5). The FASP method was per-
formed with additional features, as described below, to
check the performance of the filter before adding the sam-
ple. For phosphoproteomic labelled studies, 320 μg of
each of the three samples and 160 μg of the super-SILAC
mix were used and equally processed. Peptides were
desalted with Oasis HLB plates (Waters).
Small-scale proteome fractionation
Proteomic samples were fractionated in a StageTip
casted with four SDB-RPS disks (Empore SPE disks).
Peptides were sequentially eluted with three buffers (x1,
x2 and bufX) of increasing salt content [15]. The three
fractions were dried under vacuum and kept at −20 °C.
Peptide pellets were dissolved with 20 μl of a solution con-
taining 1 % formic acid (FA) and 2 % acetonitrile (ACN)
for LC-MS analysis. The peptide concentration was esti-
mated by reading absorbance at 280 nm with a Nanodrop
spectrophotometer (Nanodrop Technologies, Inc.).
Phosphopeptide enrichment with IMAC
Phosphoproteomic samples were dissolved with a 50 %
ACN and 0.1 % trifluoroacetic acid (TFA) solution and
incubated with the Fe (III) chelate matrix PHOS-Select
(Sigma) following the recommended slurry/peptide ratio
by Thingholm et al. [29]. Ammonia-eluted phosphopep-
tides were dried under vacuum and kept at −20 °C.
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1 % FA/2 % ACN solution and phosphopeptide concen-
tration was determined as described above.
Reverse phase chromatography and mass spectrometry
Peptide identification and abundance measurements were
performed on an Orbitrap Elite mass spectrometer coupled
to an Ultimate 3000 Rapid Separation LC system (both
Thermo Scientific). Approximately, 0.3 μg in 1.2 μl of
proteomic fractions x1 and x2, and 2.5 μl of proteomic frac-
tion bufX (undetermined concentration with Nanodrop)
were pre-concentrated on a 75 μm ID reversed-phase (RP)
trapping column (Dionex, Acclaim PepMap Nano Trap
column, C18, 75 μm i.d. x 2 cm, 3 μm particle size) in 0.1 %
TFA followed by separation on a 75 μm ID RP column
(Dionex, Acclaim PepMap100 RSLC nano column, C18,
75 μm i.d. x 50 cm, 3 μm particle size) using a binary
gradient (solvent A: 0.1 % FA in water and solvent B:
0.1 % FA in 80 % ACN). Approximately, 1 μg of
phosphopeptides in 6 μl were pre-concentrated and
separated using the same columns and equipment as
before. Elution and MS specifications are described in
supplementary Additional file 1.
Data processing
Raw data were processed with MaxQuant version
1.5.2.8 [30, 31]. MS and MSMS were searched against
concatenated reverse-decoy Swiss-Prot Homo sapiens data-
base version 2014 08 (41178 sequences) using the An-
dromeda search engine [32]. The database search was
performed with an initial mass tolerance of ±20 ppm for
precursor masses and ±0.6 Da for collision-induced dis-
sociation (CID) and multistage activation (MSA) ion trap
fragment ions. Two analysis groups were made in Max-
Quant to create one combined analysis for all proteome
and phosphoproteome data. Cysteine carbamidomethyla-
tion was used as a fixed modification for both groups. For
the proteome data, variable modifications included methio-
nine oxidation and protein N-terminal acetylation. The
phosphoproteome data was additionally searched with
serine, threonine and tyrosine phosphorylation included as
variable modifications. Two missed cleavages were allowed.
The re-quantify feature was enabled and the match be-
tween runs feature was disabled. The false discovery rate
was set at 0.01 for peptides, proteins, and phosphosites;
and the minimum peptide length allowed was 6 amino
acids. Everything else was set to the default values. A site
localization probability of at least 0.75 was used as the
threshold for the localization of phosphoresidues.
Microsoft Excel was used for downstream analysis of
MaxQuant proteome and phosphoproteome results. Both
data sets were further analysed with FunRich [33] for
functional enrichment analysis with the FunRich database
of molecular functions.Step-wise protocols
Key reagents and equipment
○ Urea pellets (Sigma, #U1250)
○ Microcon-30 kDa Centrifugal filters (Millipore,
#MRCF0R030)
○ 1.5 ml and 2 ml protein-low-binding tubes
➢ e.g., Eppendorf ProteinLobind tubes (Eppendorf,
#022431081 and #022431102)
○ Oasis HLB 96-well μElution plate (2 mg sorbent per
well, Waters #186001828BA) for proteomic samples
and Oasis HLB 96-well plate (10 mg sorbent per well,
Waters #18600128) for phosphoproteomic samples
○ Empore™ SDB-RPS extraction disc
(3 M, #00051115088162)
○ Empore™ C8 extraction disc (3 M, # 00051115088049)
○ PHOS-Select™ iron affinity gel (Sigma, #P9740)
○ Tools to cast SDB-RPS and C8 disks onto a pipette tip
➢ e.g. 16 gauge, Kel-F Hub NDL, 2 in, point style 3
needle (Hamilton, #90516) and plunger assembly
(Hamilton, #1122-01)
○ 1.5 ml tube holder (GL Sciences, Inc. #5010-21514)
○ Thermal shaker
➢ e.g. Thermomixer C (Eppendorf, #5382000015)
○ 1.5 ml-tube centrifuges
➢ e.g. AccuSpin Micro 17R (Fisher Scientific,
#13100676) for FASP
➢ e.g., Rotina 380R (Hettich, #1706-01) for StageTip
spinning
○ 96-well plate centrifuge
➢ e.g. Universal 320R (Hettich, #1406-01)
○ Tube rotator
➢ e.g. SB3 (Stuart, no code provided)
○ Equipment for the determination of peptide
concentration
➢ e.g., Nanodrop spectrophotometer ND-1000
(Nanodrop Technologies, Inc.)
○ Speed vacuum lyophilisator
➢ e.g., CentriVap centrifugal vacuum concentrator
(LabConco, #7810033) and CentriVap cold trap
(LabConco, #7385030)
FASP of AML-proteomic samples
1. To the AML protein sample containing the
super-SILAC mix, add 1 M DTT (prepared in
0.1 M Tris–HCl pH 7.6) to a final concentration
of 0.1 M. Heat at 95 °C under shaking at
500 rpm in a thermoshaker during 5 min.
2. Test the FASP filter: add 500 μl of the FASP-urea
buffer (8 M urea in 0.1 M Tris–HCl pH 8.5, freshly
prepared) and centrifuge at 12000 xg at room
temperature (centrifugation will be carried out at
the same speed and temperature in this FASP
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pass through the filter. Discard filters that show
complete filtration as they will not retain proteins
on the filter unit (Fig. 4). Keep centrifuging the
working filters to fully condition the unit for further
15–20 min leaving just a thin layer of buffer on top
of the filter membrane.
3. Add FASP-urea buffer to the samples to reduce 4 %
SDS to 0.5 %. Mix properly.
4. Transfer the samples to the conditioned filters and
centrifuge for 15–20 min until most of the sample is
filtrated.
5. Add 200 μl of the FASP-urea buffer and centrifuge
for 15 min. Discard flow through when necessary.
❖ Check that filters always have sample on the
membrane (See Troubleshooting Table 1)
6. Add 100 μl of 50 mM iodoacetamide prepared in
the FASP-urea buffer. Mix at 650 rpm in the
thermoshaker for 1 min and incubate in the dark
for 20 min. Centrifuge for 10–15 min.
7. Add 100 μl of the FASP-urea buffer and centrifuge
for 10–15 min. Repeat this step one more time.Fig. 4 Picture of a working (right) and failed (left) FASP centrifugal
filter. A large volume in the filtrate after a short spin (5 min) helps to
identify non-retaining-protein-membrane filters8. Add 100 μl of 50 mM Ambic and centrifuge for
10 min. Repeat this step two more times.
9. Dissolve trypsin in 50 mM Ambic and add to the
samples in a 1:50 ratio. The final volume should be
75–100 μl for efficient protease activity.
10. Mix at 650 rpm for 1 min. To minimize the
evaporation, wrap the tubes in parafilm and do not
discard the filtrated Ambic in the collecting tubes.
11. Incubate at 37 °C for 16 h.
12. Transfer the filter units to new collecting tubes and
shake the filters at 650 rpm in a thermoshaker for
1 min to homogenize the peptide matrix. Then,
centrifuge for 10 min.
13. Add 40–50 μl 50 mM Ambic and centrifuge for
10 min. Repeat this step twice.
14. Add 50 μl 0.5 M NaCl and centrifuge for 10 min.
15. Transfer the peptide solution to protein-low-
binding tubes.
16. Measure protein concentration with Nanodrop: 2–3
replicates, 1.5-2 μl per sample. Calculate final peptide
content by assuming that a peptide solution of 1 μg/
μl will have an absorbance at 280 nm of 1.1 [12].
From 30 μg of starting material (AML sample
and super-SILAC mix), we recovered 16–22 μg
of peptides (53-73 % recovery).
❖ The standard FASP peptide recovery (40–60 %)
confirms a satisfactory FASP (See Troubleshooting
Table 1)
17. Acidify with 10 % TFA to reach a final
concentration of 0.5 % TFA. Check that pH (with
pH strips) is lower than 4.
18. Desalt the peptides using Oasis HLB 96-well μelution
plate using 0.1 % FA and 80 % ACN/0.1 % FA as
binding and elution buffers, respectively. The
desalting protocol is described in Additional file 1.FASP of AML-phosphoproteomic samples
FASP with the SILAC-labelled phosphoproteomic sam-
ple was carried out as described above for the proteomic
samples. Although the Microcon centrifugal filters can
process 300 μg of protein in our hands, we used two cen-
trifugal filters loading 240 μg of mixed AML proteins
and super-SILAC mix in each. After dilution of SDS
with the FASP-urea buffer, the large-volume sample
might require several centrifugal rounds to concentrate
the sample before starting the FASP procedure. From
480 μg of starting material, we recovered 210–258 μg
of peptides (44 %–54 % recovery). We acidified phos-
phoprotemic samples at a peptide concentration of
0.10–0.15 μg/μl to avoid peptide precipitation. We used
Oasis HLB 96-well plate 10 mg to desalt the peptides of
these samples. The desalting protocol is described in
Additional file 1.
Table 1 Troubleshooting
Problem Possible reason Solution
The centrifugal unit spun all the protein
sample. No sample left on the membrane.
Faulty filter Collect the filtrate and place it onto a new tested and
conditioned spin filter
Filter membrane displaced due to the tight
insertion of the filter into the collection tube
Find a collection tube where a new tested and conditioned
filter can be inserted with no friction. Collect the filtrate onto it.
Low peptide recovery in the filtrate
(<40 %)
Severe filter clogging Pipette gently up and down to homogenize when adding a
new solution, without touching the filter membrane
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1. Cast four-disk-SDB-RPS StageTips with the help of a
16 gauge needle and a plunger assembly onto a
200 μl-pipette tip. Place the tip on a 2 ml tube with
a tube adaptor.
2. Resuspend the dried peptide pellets in 60 μl of 0.2 %
TFA and briefly spin to remove insoluble particles.
3. Condition the SDB-RPB microcolumn with 100 μl
ACN.
4. Wash the microcolumn with 100 μl water.
5. Equilibrate the microcolumn twice with 100 μl 0.2 %
TFA.
6. Load the sample onto the microcolumn.
7. Wash the microcolumn twice with 100 μl 0.2 %
TFA.
8. Elute sequentially, and use a new 1.5 ml protein-
low-binding tube per buffer, with:- 100 μl 100 mM ammonium formate/40 % ACN/
0.5 % FA (x1)
- 100 μl 150 mM ammonium formate/60 % ACN/
0.5 % FA (x2)
- 100 μl 5 % ammonium hydroxide/80 % ACN (bufX)
All the buffers should be freshly prepared. At steps 3–
5 centrifuge at 1700 xg for 3 min, at step 6 at 800 xg for
3 min and at steps 7–8 at 1200 xg for 3 min.
Phosphopeptide enrichment with IMAC
1. Incubate PhosSelect gel with 1 ml of 50 % ACN/
0.1 % TFA (IMAC binding buffer) in a rotator for
1 min. Centrifuge the beads at 1700 xg for 2 min.
Remove the supernatant. Repeat these steps two
more times to complete equilibration and keep the
beads at a 50 % slurry in IMAC binding buffer.
2. Dissolve dried peptide pellets with 200 μl of IMAC
binding buffer. After vortexing for a while and
spinning down insoluble particles, place the
peptide solutions in a 0.5 ml protein-low-binding
tube.
3. Add equilibrated beads to the peptide solution
(keeping a ratio of 50 μl of the 50 % slurry/120 μg
peptide; i.e. 88, 93 and 108 μl of beads to 210, 223and 258 μg of peptides) and rotate at room
temperature for 30 min.
4. While rotating, place a C8 disk onto a 200 μl pipette
tip with the tools described earlier. Place the tip on
a 2 ml tube with a tube adaptor and equilibrate with
200 μl of IMAC binding buffer spinning at 800 xg
for 3 min.
5. Collect the beads by gentle centrifugation and place
them on the StageTips. Centrifuge the microcolumn
at 800 xg for 3 min.
6. Wash the beads with 200 μl of IMAC binding buffer
three times using the same centrifugation parameters.
Discard the flow-through when it reaches the bottom
of the tip.
7. Place the microcolumn in a new 2 ml protein-low-
binding tube.
8. Elute phosphopeptides by three sequential additions
of 150 μl of 1.4 % ammonia/60 % ACN, spinning at
500 xg for 5 min.
9. Split the 450 μl eluate in two 1.5 ml protein-low-
binding tubes before drying under vacuum.
10.Add 20 μl of the 1 % FA/2 % ACN solution to one
of the tubes containing the dried phosphopeptides.
After resuspension, add the solution to the other
tube to keep a single sample tube with high
concentration of phosphopeptides for MS analysis.Troubleshooting
Troubleshooting recommendations can be found in
Table 1.Additional file
Additional file 1: Additional procedures of the proteomic and
phosphoproteomic workflows, describes our LC-MS methods and a
standard desalting protocol with Oasis HLB plates. (DOCX 20 kb)Abbreviations
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